Q&A: Symbiosis: US FDA boost at Scottish aseptic viral vector plant

Colin MacKay, CEO of Symbiosis Pharmaceutical Services, recently took part in a Q&A interview with BioProcess Insider, discussing US Food and Drug Administration (FDA) approval and what it means for Symbiosis in terms of meeting industry demands now and post-Brexit.The article provides insight into the significance of US FDA accreditation, the Innovate UK grant and the challenges Brexit poses for Symbiosis and… Read More

Colin Mackay, CEO of Symbiosis

Steady growth in 2017 points to a successful year ahead for Symbiosis

Another year has passed here at Symbiosis HQ and I’m pleased to report that 2017 has been another strong year of sustained, profitable, growth for the company.Our underlying positive growth trend has continued, and aligns well with our strategic focus on developing the business in the North American market alongside our more established client base in Europe. Our efforts to proactively build… Read More

Colin Mackay, CEO of Symbiosis

A positive end to a positive year at Symbiosis

It may feel like only yesterday we were planning for 2016, but here we are at the end of another successful year. While the last 12 months have seemingly gone in a flash, it’s been another encouraging year at Symbiosis Pharmaceutical Services.With the support of our clients, staff, suppliers and partners, I’m pleased to say it’s been another steady year of growth… Read More

Qualified Person Release

The Good CMO Guide – What should small biotechs look for when outsourcing clinical trial manufacturing?

What kind of relationship are you looking for? It’s the first question that should be on the minds of biotech companies once the decision to outsource clinical trial manufacturing of parenterals to a CMO has been made. Is it a transactional relationship? One where a service is sourced and swiftly delivered without much in the way of long-term planning or on-going work… Read More

A review of BIO International Convention 2016

The dust has settled and it’s business as usual here in Stirling after BIO International Convention in San Francisco but we just wanted to take a moment to reflect on our main take-homes from the event…There is certainly a feeling of general buoyancy and positivity in the industry. It is clear that the investment community continues to see the biotech sector as… Read More

Biotech Boom Fuels Parenteral Market

Colin MacKay, CEO of Symbiosis Pharmaceutical Services assesses the trends driving parenteral manufacturing in this guest blog as featured on Contract Pharma.“There are a number of factors that are influencing the growing demand for aseptically-processed parenteral products. The continued growth of the biotech sector and increased funding available are major drivers, while mergers and acquisitions within the contract manufacturing organization (CMO) space… Read More

Is it really location, location, location in sterile manufacturing?

The pharmaceutical industry is a truly global sector. Within drug development, clinical trials are now conducted all over the world, so does it really matter where your sterile product manufacturer is based?Away from factors such as locality, one of the key drivers of this decision will be the regulation of injectable medicines. So what are the regulatory differences between say Europe and… Read More

It’s all change in Europe’s sterile manufacturing market… or is it?

The last six months has seen some major changes to the sterile manufacturing landscape here in Europe. There have been a number of exits and acquisitions that have no doubt made the market sit up and listen but has anything really changed?At an industry level, the demand for sterile injectable manufacturing capability is evident and industry publications regularly publish indicators of growth… Read More

Get In Touch